Maratha Headlines

Chronic Obstructive Pulmonary Disease Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

 Breaking News
  • No posts were found

Chronic Obstructive Pulmonary Disease Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

September 28
18:54 2022
Chronic Obstructive Pulmonary Disease Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market
Chronic Obstructive Pulmonary Disease Market
DelveInsight’s ‘Chronic Obstructive Pulmonary Disease (COPD)-Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the COPD, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

DelveInsight’sChronic Obstructive Pulmonary Disease (COPD)-Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the COPD, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The COPD market report provides current treatment practices, emerging drugs, market share of the individual therapies, and the current and forecasted 7MM COPD market size from 2019 to 2032. The Report also covers current COPD treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Some of the key facts of the Chronic Obstructive Pulmonary Disease Market Report:

  • In the epidemiology model of COPD, there are multiple age groups referred ranging from 18–44 years, 45–54 years, 55–64 years, 64–74 years, and 75+ years, for COPD. In the US, the highest number of cases were reported in the age group of 55–64 years i.e. 4,601,558, in 2020. 
  • In 2020, a lower number of males were affected by this disease contributing  6,588,516 total diagnosed prevalent population of COPD in the United States. In comparison, there were 10,867,088 female cases in 2020.
  • In 2020, the US had 2,967,453, 8,727,802, 4,538,457 and 1,221,892 cases of GOLD 1, GOLD 2, GOLD 3, and GOLD 4, respectively based on severity of airflow limitation.

 

Key Benefits of the Chronic Obstructive pulmonary disease Market report:

 

  • The report covers a descriptive overview of COPD, explaining its signs and symptoms, causes, classification, and currently available therapies.
  • Comprehensive insight has been provided into COPD epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for COPD is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the COPD market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM COPD market.

 

Got queries? Click here to know more about the Chronic Obstructive Pulmonary Disease Market Landscape 

 

Chronic Obstructive Pulmonary Disease Overview

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

The main risk factor for COPD is tobacco smoking, but other environmental exposures such as biomass fuel exposure and air pollution may contribute. Besides exposures, host factors predispose individuals to develop COPD. These include genetic abnormalities, abnormal lung development, and accelerated aging. Chronic and progressive dyspnea is the most characteristic symptom of COPD. Cough with sputum production is present in up to 30% of patients

 

Chronic Obstructive Pulmonary Disease Epidemiological Insight

  • The Diagnosed prevalent population of COPD in the 7MM was 34,640,030 in 2020. These cases of Chronic Obstructive Pulmonary Disease (COPD) in the 7MM are expected to increase throughout the study period, i.e., 2019–2032.
  • The estimates suggest a higher diagnosed prevalence of COPD in the United States with  17,455,605 diagnosed cases in 2020 which is expected to increase during the forecast period (2021–2032). 
  • Among the five European countries, Germany has the highest diagnosed prevalent population followed by Italy and France. On the other hand, Spain had the lowest diagnosed prevalent population. 

 

Chronic Obstructive Pulmonary Disease  Epidemiological Segmentation

  • COPD gender-specific Diagnosed Prevalent cases 
  • COPD age-specific diagnosed Prevalent cases 
  • COPD diagnosed prevalent cases 
  • COPD diagnosed prevalent cases based on the severity of airflow 
  • COPD diagnosed in prevalent cases based on symptoms and exacerbation history COPD

 

Chronic Obstructive Pulmonary Disease Market Outlook 

COPD prevalence is dramatically increasing worldwide; however, there are few effective therapies, and none of the treatments currently available prevent the progression of the disease or target all of the hallmark features. The development and progression of COPD are heterogeneous, which has hampered the development of new therapies.

Depending on the severity of the COPD, short-acting or long-acting bronchodilators were introduced. Short-acting bronchodilators last about 4–6 h and should be used when needed only. Long-acting bronchodilators last about 12 h or more and are used every day. Patients at risk of exacerbations began to use long-acting anticholinergics (LAMA) or combinations of inhaled long-acting β2-agonists (LABA) and corticosteroids (ICS). The LABA/LAMA combination was suggested for more symptomatic patients and those at greater exacerbation risk. 

Roflumilast, a phosphodiesterase-4 inhibitor, is an alternative approach to prevent exacerbations in chronic bronchitis and a history of prior exacerbations. Although the overall approach was lauded for its personalized basis, many of the recommendations were not strictly evidence-based. A key limitation of these recommendations reflected the unclear role of ICS in COPD, with evidence suggesting that the widespread use of these agents persists.

 

COPD Market Drivers 

  • Increasing prevalence of COPD
  • Emergence in the development of emerging therapies
  • Personalized treatments
  • Entry of the ‘Act earlier’ concept into the market
  • Improvement in diagnostic techniques
  • Growing demand for fixed-dose combinations

 

COPD Market Barriers 

  • Late recognition of COPD
  • High cost of treatment
  • Challenges in existing therapies
  • Patient-related barriers
  • Drug failure
  • Availability of generics

Learn more by requesting for sample @chronic obstructive pulmonary disease Market Landscape

 

Chronic Obstructive Pulmonary Disease  Key Companies  

  • Sanofi Pharma 
  • Regeneron Pharma
  • Verona Pharma 
  • and many others 

 

Chronic Obstructive Pulmonary Disease  Therapies 

  • Ensifentrine
  • Dupixent (Dupilumab)
  • Itepekimab
  • and many others 

 

Table of Contents

  •  Key Insights 
  •  Report Introduction
  • Executive Summary of Chronic Obstructive Pulmonary Disease 
  • Disease Background and Overview
  • Epidemiology and patient population 
  • Chronic Obstructive Pulmonary Disease   Emerging Therapies
  • Chronic Obstructive Pulmonary Disease  Market Outlook
  • Market Access and Reimbursement of Therapies
  • Market Drivers and Market Barriers 
  • Appendix
  • Chronic obstructive pulmonary disease  Report Methodology 
  • DelveInsight Capabilities
  • Disclaimer
  •  About DelveInsight 

  Click here to read more about chronic obstructive pulmonary disease Market 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/